A5078585973- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Galectins and Cancer Biology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Gastrointestinal Tumor Research and Treatment
- Platelet Disorders and Treatments
- Immune cells in cancer
- Voice and Speech Disorders
- Head and Neck Surgical Oncology
- Single-cell and spatial transcriptomics
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Advanced Proteomics Techniques and Applications
- Blood disorders and treatments
- Brain Metastases and Treatment
- Advanced Biosensing Techniques and Applications
- Chemokine receptors and signaling
- Tracheal and airway disorders
National Cancer Institute
2025
National Institutes of Health
2013-2025
Center for Cancer Research
2025
Poseida Therapeutics (United States)
2024
National Heart Lung and Blood Institute
2013-2022
United States Public Health Service Commissioned Officers Association
2021
Office of the Director
2020
Centre d’Immunologie de Marseille-Luminy
2013
Inserm
2013
EsSALUD
1980
Acquired aplastic anemia results from immune-mediated destruction of bone marrow. Immunosuppressive therapies are effective, but reduced numbers residual stem cells may limit their efficacy. In patients with that was refractory to immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led clinically significant increases in blood counts almost half the patients. We combined standard immunosuppressive therapy eltrombopag previously untreated severe anemia.
Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B-cell receptor (BCR) signaling. Ibrutinib, a Bruton tyrosine kinase inhibitor, disrupts BCR signaling leads to the egress of tumor from microenvironment. Although on-target effects CLL well defined, impact microenvironment is less studied. We therefore sought characterize in vivo ibrutinib microenvironment.Patients received...
Ibrutinib is associated with bleeding-related adverse events of grade ≤2 in severity, and infrequently ≥3 events. To investigate the mechanisms bleeding identify patients at risk, we prospectively assessed platelet function coagulation factors our investigator-initiated trial single-agent ibrutinib for chronic lymphocytic leukemia. At a median follow-up 24 months recorded 55% 85 patients. No occurred. Median time to event was 49 days. The cumulative incidence an plateaued by 6 months,...
Abstract Corticosteroids have been used for decades to modulate inflammation therapeutically, yet there is a paucity of data on their effects in humans. We examined the changes cellular and molecular immune system parameters, or “immunome”, healthy humans after systemic corticosteroid administration. multiplexed techniques query immunome 20 volunteers at baseline, intravenous hydrocortisone (HC) administered moderate (250 mg) low (50 doses, provide insight into how corticosteroids exert...
Background The powerful ‘graft versus leukemia’ effect thought partly responsible for the therapeutic of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (AML) provides rationale investigation immune-based therapies this high-risk blood cancer. There is considerable preclinical evidence potential synergy between PD-1 immune checkpoint blockade and hypomethylating agents already commonly used disease. Methods We report here results 17 H-0026 (PD-AML, NCT02996474 ), an...
Background In chronic lymphocytic leukemia lenalidomide causes striking immune activation, possibly leading to clearance of tumor cells. We conducted this study investigate the mechanism action and basis for its unique toxicities in leukemia.Design Methods Patients with relapsed were treated 20 mg (n=10) or 10 (n=8) daily 3 weeks on a 6-week cycle. Correlative studies assessed expression co-stimulatory molecules cells, T-cell cytokine levels, changes lymphocyte subsets.Results Lenalidomide...
Clinical trials of ibrutinib combined with anti-CD20 monoclonal antibodies (mAb) for chronic lymphocytic leukemia (CLL) report encouraging results. Paradoxically, in preclinical studies, vitro was reported to decrease CD20 expression and inhibit cellular effector mechanisms. We therefore set out investigate effects vivo treatment that could explain this paradox.Patients received single-agent (420 mg daily) on an investigator-initiated phase II trial. Serial blood samples were collected...
Abstract Background Coronavirus disease 2019 (COVID-19) requiring hospitalization is characterized by robust antibody production, dysregulated immune response, and immunothrombosis. Fostamatinib a novel spleen tyrosine kinase inhibitor that we hypothesize will ameliorate Fc activation attenuate harmful effects of the anti-COVID-19 response. Methods We conducted double-blind, randomized, placebo-controlled trial in hospitalized adults oxygen with COVID-19 where patients receiving standard...
Ibrutinib, a Bruton tyrosine kinase inhibitor, is new targeted agent approved by the US Food and Drug Administration for treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, Waldenström macroglobulinemia. Ibrutinib overall well tolerated but long-term required until disease progression or intolerable toxic effects occur. Little known regarding its cutaneous adverse effects.To describe hair nail manifestations associated with use ibrutinib CLL.Prospective study 66 patients...
Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous disease that characterized by abnormal clonal proliferation of progenitor cells found predominantly within the bone marrow (BM) and blood. Recent studies suggest genetic phenotypic alterations in BM microenvironment support leukemogenesis allow leukemic to survive evade chemotherapy-induced death. However, despite substantial evidence indicating role tumor–host interactions AML pathogenesis, little known about complex BM....
Abstract There is no standard or widely effective treatment of patients with moderate aplastic anemia (MAA) hypo-productive uni-lineage cytopenias (UC). Eltrombopag (EPAG), a small molecule thrombopoietin mimetic, has previously been shown to result in durable multi-lineage hematologic responses low toxicity refractory severe (SAA). Its safety and efficacy MAA are unknown. This prospective phase 2 study enrolled untreated treated UC clinically relevant cytopenias. EPAG was administered at...
Abstract Genetic mutations associated with acute myeloid leukemia (AML) also occur in age-related clonal hematopoiesis, often the same individual. This makes confident assignment of detected variants to malignancy challenging. The issue is particularly crucial for AML posttreatment measurable residual disease monitoring, where results can be discordant between genetic sequencing and flow cytometry. We show here that it possible distinguish from hematopoiesis resolve immunophenotypic identity...
Abstract Immune stimulation contributes to lenalidomide’s antitumor activity. Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature, autoreactive B cells in secondary lymphoid tissues, blood, and bone marrow progressive immune dysfunction. Previous studies CLL indicated that lenalidomide can repair defective T cell function vitro. Whether activation required for clinical response remains unclear. In this study, we report changes microenvironment patients with...
TPS6117 Background: HPV-OPC is caused primarily by HPV16. Prognosis following standard-of-care (SOC) treatment, (surgery followed adjuvant radiotherapy (RT), or concurrent chemoRT (CRT)) favorable, with >80% 5-year recurrence-free survival (RFS). However, RT toxicity including tissue fibrosis results in long-term swallowing dysfunction and impacts quality of life (QOL). NAC treatment (DC) surgery has resulted clinical-to-pathologic downstaging pathologic complete response (pCR) avoidance...